Clinical trial NCT05878327: Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia
Official title: Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Livedoid Vasculitis
Keywords: Livedoid Vasculitis
smoking
thrombophilia
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2023-05-26
Enrollment: 15
Sex: ALL
Minimum age (years): 10
Maximum age (years): 85
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients treated for livedoid vasculopathy at the clinics of Dermatology of the University hospitals of Zurich, Basel and Bern.

Brief summary: A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia.

Detailed description: A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy. Patients with a history of livedoid vasculopathy are asked to participate in the study. The presence of Livedoid vasculopathy must be confirmed by a histologic specimen. After reading the patient information and if the informed consent is signed patients are included in the study. Patients are questioned about their smoking history and blood is drawn in order to perform a screening for thrombophilia. The presence of a history of smoking and thrombophilia is compared to the general Swiss population.

Eligibility criteria: Inclusion Criteria:

* History of livedoid vasculopathy

Exclusion Criteria:

* Diagnosis was not proved by biopsy specimen
* A different reason than livedoid vasculopathy has been found for the symptoms of the patient
* No informed consent by the patient

Primary outcomes:
measure: Smoking history: Patients will be asked if they currently smoke or if they are former smokers. If one of both items is yes, it means a positive answer.
timeFrame: 22 months
Secondary outcomes:
measure: Thrombophilia screening: the following parameters will be determined in every participant: Factor V Leiden, Prothrombin 20210; Protein C, Protein S, Antithrombin III, Beta 2 Glykoprotein 1, Lupus Antikoagulans
timeFrame: 22 months
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University hospital of Basel
city: Bern
country: Switzerland
facility: University hospital of Bern
city: Zurich
country: Switzerland
facility: University hospital Zurich
Study officials:
affiliation: University Hospital Zurich, Dept. of Dermatology
name: Juerg Hafner, Prof, MD
role: PRINCIPAL_INVESTIGATOR
References: